Mark Bornstein, DO
Family Medicine · Berkley, MINPI 1164982203
Payments from drug & device makers
Across 556 payments — averaging $25.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$4K
- Viiv Healthcare Company$3K
- Merck$3K
- AbbVie$597
- Johnson & Johnson$315
- Lilly USA, LLC$293
- plus $3K from 26 others
Across 14 payments — averaging $221.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$2K
- Viiv Healthcare Company$673
What the payments were for
- Travel & lodging$1,84613%
- Food & beverage$12,36487%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 189 | $4,173 |
| Viiv Healthcare Company | 159 | $3,344 |
| Merck | 35 | $2,875 |
| AbbVie | 38 | $597 |
| Johnson & Johnson(2 entities) | 9 | $315 |
| Lilly USA, LLC | 13 | $293 |
| AstraZeneca | 16 | $267 |
| Antares Pharma, Inc. | 11 | $245 |
| Novo Nordisk | 7 | $231 |
| Pfizer | 14 | $223 |
| Axsome Therapeutics, Inc. | 9 | $223 |
| Theratechnologies Inc. | 5 | $196 |
| Halozyme Inc | 4 | $196 |
| Napo Pharmaceuticals Inc | 7 | $139 |
| Janssen Products, LP | 1 | $134 |
| Otsuka America Pharmaceutical, Inc. | 5 | $117 |
| GSK | 6 | $102 |
| Lundbeck LLC | 6 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $66 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $57 |
| Seqirus USA Inc | 3 | $55 |
| Indivior Inc. | 2 | $47 |
| Corcept Therapeutics | 1 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Boston Scientific | 1 | $29 |
| Verity Pharmaceuticals Inc. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Tolmar, Inc. | 1 | $17 |
| Lucid Diagnostics Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Alk-abello, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,210 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 138 | $591,547 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 35 | $200,171 |
| DovatoDolutegravir Sodium/Lamivudine | 24 | $79,053 |
| PrezcobixDarunavir/Cobicistat | 22 | $49,640 |
| OzempicSemaglutide | 48 | $45,325 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 12 | $44,247 |
| MounjaroTirzepatide | 32 | $42,546 |
| FarxigaDapagliflozin Propanediol | 27 | $30,005 |
| JardianceEmpagliflozin | 18 | $25,986 |
| EliquisApixaban | 31 | $23,054 |
| IsentressRaltegravir Potassium | 12 | $22,524 |
| TrulicityDulaglutide | 19 | $21,204 |
| Maraviroc | 12 | $16,920 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,993 |
| Diclofenac Sodium | 28 | $7,467 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $4,173 | $591,547138 claims |
| Janssen Products, LPSymtuza | $134 | $200,17135 claims |
| Viiv Healthcare CompanyDovato, Triumeq | $3,344 | $123,30136 claims |
| Lilly USA, LLCMounjaro, Trulicity | $293 | $63,75051 claims |
| Johnson & JohnsonPrezcobix | $315 | $49,64022 claims |
| Novo NordiskOzempic | $231 | $45,32548 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $267 | $41,64352 claims |
| PfizerEliquis | $223 | $23,05431 claims |
| MerckIsentress | $2,875 | $22,52412 claims |
| GSKAnoro Ellipta | $102 | $5,13611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Berkley
- Paul BensonBerkley$4.2M
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.